Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PP-007 in acute ischemic stroke
NCT04677777Phase 1Completed
- Sponsor
- Prolong Pharmaceuticals
- Start
- Apr 2024
- Primary completion
- Feb 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Sanguinate in ischemic stroke, sponsored by Prolong Pharmaceuticals. Primary endpoints: Vital Signs at 90 days, Heart Rate at 90 days and 14 more. Started Apr 2024; status: completed.
02
Drugs
Sanguinate
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT04677777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04677777.